ATROVENT NASAL SPRAY 0.03% Rx
Generic Name and Formulations:
Ipratropium bromide 0.03% (21mcg/spray); aqueous soln.
Boehringer Ingelheim Pharmaceuticals
Indications for ATROVENT NASAL SPRAY 0.03%:
Rhinorrhea associated with allergic and nonallergic perennial rhinitis.
Adults and Children:
<6yrs: not recommended. ≥6yrs: 2 sprays in each nostril 2–3 times daily.
Allergy to atropine or its derivatives.
Avoid eyes. Narrow-angle glaucoma. GI or GU obstruction. Pregnancy (Cat.B). Nursing mothers.
Epistaxis, pharyngitis, nasal dryness or irritation, other nasal symptoms, nausea.
Nasal spray—30mL (345 sprays)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Improving Performance of Everyday Activities Is Critical in Schizophrenia
- Analysis Finds Lithium Maintenance Most Effective as Monotherapy in Bipolar Disorder
- Web-Based Intervention Targets Parental Behaviors That May Affect Adolescent Anxiety, Depression
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Examining Associations Between Diabetes and Effects on Cognition
- Untreated Depression Common in Women of Childbearing Age
- Incidence of Psychiatric Disorders in Rheumatoid Arthritis
- Effect of Antidepressant Class, Dose on Pediatric Anxiety Disorders